ABSTRACT

Background: Pneumonia and acute bronchitis are the major life threatening condition in children. Especially in India, these conditions are very common and around 4 lakhs children aged below five years die every year from multiple diseases cause by acute respiratory infection. Purpose: To examine the prescription behaviour of glucocorticoids and bronchodilators in pneumonia and acute bronchitis in children. Methods: The approval of the human ethics committee was obtained from Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore. Enrolled were the patients who met the study's eligibility requirements. The patient's demographic was entered. Data on the patient's demographics, clinical condition, and medications was gathered and entered into specially created documentation forms. Descriptive statistics were used to evaluate the obtained data. Results: There were 101 children involved in the study, ranging in age from 1 year to 15 years. It includes males and females equally. Most of the prescriptions contained Bronchodilators and antibiotics. Among them, the bronchodilators group of drugs Levo salbutamol nebulizer (35.145%), in the corticosteroid group, prednisolone syrup (16.25%), and in antibiotics group,cephalosporins (68%) were prescribed mostly. syrup formulations containing prednisolone and inhaler formulation bronchodilators were used widely. Conclusion: As a first-line choice bronchodilator Lev. salbutamol is used in treating pneumonia and acute bronchitis. The first line choice of corticosteroids is prednisolone syrup. Cephalosporins are the antibiotics that are used in a wide range for both diseases whereas all bronchodilators were given in nebulization form and corticosteroids were given in oral route. All the prescribed drugs were within the FDA-recommended dose range in children. Keywords: Acute bronchitis, antibiotics, bronchodilators, corticosteroids, pneumonia
Publication date: 01/06/2025

https://ijbpas.com/pdf/2025/June/MS_IJBPAS_2025_9147.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.6.9147